|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNRNP70 |
Gene summary for SNRNP70 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNRNP70 | Gene ID | 6625 |
| Gene name | small nuclear ribonucleoprotein U1 subunit 70 | |
| Gene Alias | RNPU1Z | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | P08621 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6625 | SNRNP70 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.26e-10 | 6.89e-01 | -0.0811 |
| 6625 | SNRNP70 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.49e-05 | 3.43e-01 | -0.1954 |
| 6625 | SNRNP70 | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.64e-04 | 4.01e-01 | -0.1207 |
| 6625 | SNRNP70 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.89e-05 | 5.10e-01 | -0.1464 |
| 6625 | SNRNP70 | HTA11_1391_2000001011 | Human | Colorectum | AD | 8.10e-16 | 8.59e-01 | -0.059 |
| 6625 | SNRNP70 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.32e-08 | 5.59e-01 | 0.096 |
| 6625 | SNRNP70 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.34e-08 | 6.19e-01 | 0.0338 |
| 6625 | SNRNP70 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.21e-21 | 7.85e-01 | 0.0674 |
| 6625 | SNRNP70 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.29e-05 | 4.55e-01 | 0.294 |
| 6625 | SNRNP70 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.87e-11 | 6.98e-01 | 0.281 |
| 6625 | SNRNP70 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 9.47e-14 | 8.84e-01 | 0.3859 |
| 6625 | SNRNP70 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.87e-06 | 5.31e-01 | 0.3005 |
| 6625 | SNRNP70 | A015-C-203 | Human | Colorectum | FAP | 1.86e-19 | 3.97e-01 | -0.1294 |
| 6625 | SNRNP70 | A002-C-201 | Human | Colorectum | FAP | 7.19e-07 | 1.41e-01 | 0.0324 |
| 6625 | SNRNP70 | A001-C-108 | Human | Colorectum | FAP | 2.78e-03 | -1.87e-02 | -0.0272 |
| 6625 | SNRNP70 | A002-C-205 | Human | Colorectum | FAP | 2.93e-09 | -7.64e-02 | -0.1236 |
| 6625 | SNRNP70 | A015-C-006 | Human | Colorectum | FAP | 9.89e-09 | 1.47e-01 | -0.0994 |
| 6625 | SNRNP70 | A015-C-106 | Human | Colorectum | FAP | 1.61e-08 | 3.62e-01 | -0.0511 |
| 6625 | SNRNP70 | A002-C-114 | Human | Colorectum | FAP | 2.90e-10 | 4.63e-02 | -0.1561 |
| 6625 | SNRNP70 | A015-C-104 | Human | Colorectum | FAP | 2.02e-26 | 4.20e-01 | -0.1899 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000037733 | Oral cavity | NEOLP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 81/2005 | 320/18723 | 7.96e-14 | 2.63e-11 | 81 |
| GO:000039833 | Oral cavity | NEOLP | mRNA splicing, via spliceosome | 81/2005 | 320/18723 | 7.96e-14 | 2.63e-11 | 81 |
| GO:000037533 | Oral cavity | NEOLP | RNA splicing, via transesterification reactions | 81/2005 | 324/18723 | 1.64e-13 | 5.13e-11 | 81 |
| GO:004217634 | Oral cavity | NEOLP | regulation of protein catabolic process | 92/2005 | 391/18723 | 1.77e-13 | 5.27e-11 | 92 |
| GO:003312032 | Oral cavity | NEOLP | positive regulation of RNA splicing | 19/2005 | 37/18723 | 8.91e-10 | 6.61e-08 | 19 |
| GO:190331331 | Oral cavity | NEOLP | positive regulation of mRNA metabolic process | 35/2005 | 118/18723 | 1.25e-08 | 5.94e-07 | 35 |
| GO:004802632 | Oral cavity | NEOLP | positive regulation of mRNA splicing, via spliceosome | 11/2005 | 22/18723 | 4.74e-06 | 1.01e-04 | 11 |
| GO:000645732 | Oral cavity | NEOLP | protein folding | 45/2005 | 212/18723 | 5.31e-06 | 1.10e-04 | 45 |
| GO:003133034 | Oral cavity | NEOLP | negative regulation of cellular catabolic process | 52/2005 | 262/18723 | 8.04e-06 | 1.57e-04 | 52 |
| GO:001050631 | Oral cavity | NEOLP | regulation of autophagy | 60/2005 | 317/18723 | 8.06e-06 | 1.57e-04 | 60 |
| GO:005068531 | Oral cavity | NEOLP | positive regulation of mRNA processing | 13/2005 | 32/18723 | 1.14e-05 | 2.10e-04 | 13 |
| GO:000989533 | Oral cavity | NEOLP | negative regulation of catabolic process | 59/2005 | 320/18723 | 2.16e-05 | 3.57e-04 | 59 |
| GO:004202632 | Oral cavity | NEOLP | protein refolding | 9/2005 | 23/18723 | 3.66e-04 | 3.49e-03 | 9 |
| GO:004217732 | Oral cavity | NEOLP | negative regulation of protein catabolic process | 25/2005 | 121/18723 | 9.29e-04 | 7.20e-03 | 25 |
| GO:006168422 | Oral cavity | NEOLP | chaperone-mediated autophagy | 6/2005 | 16/18723 | 4.64e-03 | 2.56e-02 | 6 |
| GO:0008380112 | Skin | cSCC | RNA splicing | 263/4864 | 434/18723 | 2.45e-53 | 5.13e-50 | 263 |
| GO:0000375112 | Skin | cSCC | RNA splicing, via transesterification reactions | 201/4864 | 324/18723 | 4.07e-43 | 5.10e-40 | 201 |
| GO:0000377112 | Skin | cSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 197/4864 | 320/18723 | 1.45e-41 | 1.14e-38 | 197 |
| GO:0000398112 | Skin | cSCC | mRNA splicing, via spliceosome | 197/4864 | 320/18723 | 1.45e-41 | 1.14e-38 | 197 |
| GO:0006457111 | Skin | cSCC | protein folding | 131/4864 | 212/18723 | 2.96e-28 | 1.32e-25 | 131 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa03040 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
| hsa030401 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
| hsa030402 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
| hsa030403 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
| hsa030409 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
| hsa0304014 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
| hsa0304024 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
| hsa0304034 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
| hsa0304018 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
| hsa0304019 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| SNRNP70 | STM | Breast | ADJ | DDX17,CDC42EP5,MALAT1, etc. | 1.20e-02 |  |
| SNRNP70 | LUMP | Breast | DCIS | DDX17,CDC42EP5,MALAT1, etc. | 2.42e-02 |  |
| SNRNP70 | BAS | Breast | IDC | DDX17,CDC42EP5,MALAT1, etc. | 6.15e-03 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNRNP70 | SNV | Missense_Mutation | c.372N>C | p.Glu124Asp | p.E124D | P08621 | protein_coding | tolerated(0.06) | possibly_damaging(0.758) | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| SNRNP70 | SNV | Missense_Mutation | novel | c.708N>A | p.Asp236Glu | p.D236E | P08621 | protein_coding | tolerated(0.9) | benign(0) | TCGA-BH-A0DQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| SNRNP70 | SNV | Missense_Mutation | novel | c.797C>T | p.Ser266Leu | p.S266L | P08621 | protein_coding | deleterious(0.01) | benign(0.098) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| SNRNP70 | SNV | Missense_Mutation | c.292N>G | p.Gln98Glu | p.Q98E | P08621 | protein_coding | tolerated(0.4) | benign(0.001) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| SNRNP70 | SNV | Missense_Mutation | c.653N>A | p.Arg218His | p.R218H | P08621 | protein_coding | deleterious(0.02) | possibly_damaging(0.744) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| SNRNP70 | SNV | Missense_Mutation | c.194A>G | p.Glu65Gly | p.E65G | P08621 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-F4-6854-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SNRNP70 | SNV | Missense_Mutation | c.1286N>T | p.Gly429Val | p.G429V | P08621 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SNRNP70 | SNV | Missense_Mutation | c.141N>T | p.Glu47Asp | p.E47D | P08621 | protein_coding | tolerated(0.1) | benign(0.115) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SNRNP70 | SNV | Missense_Mutation | novel | c.155N>A | p.Arg52Gln | p.R52Q | P08621 | protein_coding | tolerated(0.11) | benign(0.094) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SNRNP70 | SNV | Missense_Mutation | novel | c.170N>A | p.Pro57Gln | p.P57Q | P08621 | protein_coding | deleterious(0.05) | possibly_damaging(0.688) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |